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Mycophenolic acid, the active metabolite of mycophenolate mofetil (MMF), inhibits inosine monophosphate
dehydrogenase (IMPDH) activity. IMPDH is the rate-limiting enzyme involved in de novo synthesis of
guanosine nucleotides and catalyzes the oxidation of inosine 50-monophosphate to xanthosine 50-mono-
phosphate (XMP). We developed a highly sensitive liquid chromatographyemass spectrometry method to
quantitate XMP concentrations in peripheral blood mononuclear cells (PMNCs) isolated from the recipient
pretransplant and used this method to determine IMPDH activity in 86 nonmyeloablative allogeneic he-
matopoietic cell transplantation (HCT) patients. The incubation procedure and analytical method yielded
acceptable within-sample and within-individual variability. Considerable between-individual variability
was observed (12.2-fold). Low recipient pretransplant IMPDH activity was associated with increased
day þ28 donor T cell chimerism, more acute graft-versus-host disease (GVHD), lower neutrophil nadirs, and
more cytomegalovirus reactivation but not with chronic GVHD, relapse, nonrelapse mortality, or overall
mortality. We conclude that quantitation of the recipient’s pretransplant IMPDH activity in PMNC lysate
could provide a useful biomarker to evaluate a recipient’s sensitivity to MMF. Further trials should be
conducted to conﬁrm our ﬁndings and to optimize postgrafting immunosuppression in nonmyeloablative
HCT recipients.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Postgrafting immunosuppression for allogeneic he-
matopoietic cell transplantation (HCT) recipients often
consists of the combination of a calcineurin inhibitor and
mycophenolate mofetil (MMF) [1,2]. The development of
lower dose, nonmyeloablative conditioning increased the
availability of this potentially curative procedure to patients
who could not tolerate the toxicity of high-dose condi-
tioning regimens due to age or comorbidity [3]. Non-
myeloablative HCT relies on achieving a delicate balance
between recipient and donor cells, with the goal of ensuringedgments on page 1551.
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14.05.032sufﬁcient immunosuppression of the recipient to maximize
graft-versus-tumor effect but minimize toxicity.
After nonmyeloablative HCT, the recipient experiences at
least a short-term mixed chimerism state in which the
recipient and donor hematological cells coexist in the blood of
the recipient. The level and rate of change in donor T cell
chimerism have been correlated with several clinical out-
comes such as graft rejection, graft-versus-host disease
(GVHD), disease relapse/progression (ie, graft-versus-tumor
effect), and progression-free survival [4,5]. The observed as-
sociations between donor T cell chimerism and subsequent
clinical responses could, in part, reﬂect differences in each
recipient’s sensitivity to MMF. Early studies in non-
myeloablative HCT recipients administered MMF every
12 hours, regardless of donor type. Although recipients of
related donor grafts had acceptable engraftment rates with
MMF every 12 hours, patients receiving unrelated donor grafts
had persistent problems with graft rejection. EngraftmentTransplantation.
Table 1
Participant Characteristics
Donor Type
Related Unrelated All Participants
Total number 22 64 86
Sex, female/male (% female) 9/13 (41) 23/41 (36) 32/54 (37)
HCT-CI
0 1 (5) 8 (13) 9 (10)
1-2 3 (14) 14 (22) 17 (20)
3-4 10 (45) 23 (36) 33 (38)
5 8 (36) 19 (30) 27 (31)
Median recipient age, yr (range) 55 (20-69) 62 (27-75) 62 (20-75)
CMV-seropositive recipients 10 (45) 35 (56) 45 (53)
Kahl disease risk [27]
Low 4 (18) 22 (34) 26 (30)
Standard 14 (64) 26 (41) 40 (47)
High 4 (18) 16 (25) 20 (23)
Female donor to male recipient 8 (36) 17 (27) 25 (29)
Median donor age, yr (range) 55 (23-73) 31 (20-58) 35 (20-73)
HLA-mismatched graft 1 (5) 2 (3) 3 (4)
Conditioning regimen
2 Gy TBI þ FLU  auto 9 (41) 25 (39) 34 (40)
2 Gy TBI þ FLU þ rituximab*  auto 11 (50) 20 (31) 31 (36)
3 Gy TBI þ FLU  rituximab* 2 (9) 12 (19) 14 (16)
4-4.5 Gy TBI þ FLU 0 7 (11) 7 (8)
Postgrafting immunosuppression
MMF every 8 h 1 (5) 64 (100) 65 (76)
MMF every 12 h 21 (95) 0 21 (25)
Cyclosporine þ MMF  sirolimusy 12 (55) 49 (77) 62 (72)
Tacrolimus þ MMF  sirolimusz 10 (45) 15 (23) 24 (28)
HCT-CI indicates HCT comorbidity index; FLU, ﬂudarabine monophosphate; auto, autologous transplant.
Values are number of cases, with percents in parentheses, unless otherwise indicated.
* Rituximab given on days 3, þ10, þ24, and þ38 relative to transplant.
y Ten participants received cyclosporine þ sirolimus, 1 with a matched donor and 9 with unrelated donors.
z Five participants received tacrolimus þ sirolimus, all with unrelated donors.
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was increased by shortening the administration interval to
every 8 hours [1,6]. Because reliable engraftment was ach-
ieved, efforts have been ongoing to separate the graft-versus-
tumor effect from GVHD. Examples of such efforts include
examining the association of day þ28 T cell chimerism or
neutrophil nadirs within the ﬁrst 3 weeks post-HCT with
relapse rates (ie, graft-versus-tumor effect) and GVHD [4,5,7].
The active metabolite of MMF, mycophenolic acid (MPA), is
a selective, reversible, and noncompetitive inhibitor of inosine
monophosphate dehydrogenase (IMPDH). IMPDH is the
rate-limiting enzyme involved in de novo synthesis of gua-
nosine nucleotides; IMPDH catalyzes the oxidation of inosine
50-monophosphate (IMP) to xanthosine 50-monophosphate
(XMP) by a nicotinamide adenine dinucleotide (NAD)þ-
dependent pathway [8]. In renal transplantation patients, high
recipient IMPDH activity is associated with rejection [9]. To
date, no studies have evaluated the association of clinical
outcomes in HCT participants with recipient pretransplant
IMPDH activity, which is determined before allograft infusion
and MMF administration. Characterizing the relationship be-
tween recipient pretransplant IMPDH activity and clinical
outcomes is critical to understanding the potential beneﬁt of
alternative postgrafting immunosuppression or MMF dosing
strategies to improve outcomes in HCT recipients.
Even with nonmyeloablative HCT, however, the condi-
tioning regimen administered before the donor graft infu-
sion suppresses the bone marrow and thus decreases the
number of peripheral blood mononuclear cells (PMNCs)
available to determine IMPDH activity. Various nonradioac-
tive methods using chromatographic separations have been
used to quantify XMP, the catalytic product of the enzyme, to
indirectly evaluate IMPDH activity. Only recently were massspectrometryebased detection methods, which provide
more speciﬁcity and sensitivity, reported for XMP quantita-
tion [8]. Here we report a liquid chromatographyemass
spectrometry (LC-MS) method to measure recipient pre-
transplant IMPDH activity in PMNCs (ie, ex vivo) based on
the quantiﬁcation of XMP formation normalized by cell
count. We evaluated and validated this method in PMNC
lysates from healthy volunteers and nonmyeloablative HCT
recipients. We also evaluated factors associated with recip-
ient pretransplant IMPDH activity and the association of
recipient pretransplant IMPDH activity with clinical out-
comes in nonmyeloablative HCT recipients.
METHODS
Participant Characteristics
From November 2008 to February 2012, 105 patients participated in a
prospective ancillary biomarker study in nonmyeloablative HCT recipients
who received either a related or unrelated donor graft. Study participation did
not inﬂuence the HCT procedure, including the conditioning regimen or
postgrafting immunosuppression. Participants receiving ﬂudarabine mono-
phosphate (ﬂudarabine) and total body irradiation (TBI) conditioning with
postgrafting immuosuppression of a calcineurin inhibitor (cyclosporine or
tacrolimus) with MMF were eligible to participate. This protocol was
approved by the Institutional Review Board at the Fred Hutchinson Cancer
Research Center (Protocol 1980, Clinicaltrials.gov identiﬁer NCT00764829).
Written informed consent was obtained from all participants before study
procedures. Participant characteristics are summarized in Table 1.
The conditioning regimen (summarized in Supplemental Figure 1)
comprised ﬂudarabine (30 mg/m2/day i.v.) from day 4 to day 2 (cumu-
lative dose 90 mg/m2) followed by a single fraction of 2 to 4.5 Gy TBI on day
0 [1]. In general, the postgrafting calcineurin inhibitor was either cyclo-
sporine or tacrolimus given through day þ177, although some participants
also received sirolimus as part of postgrafting immunosuppression. MMF, at
a dose of 15mg/kg, was given at 2 different dose frequencies, either 3 times a
day (every 8 hours) to unrelated graft recipients or twice a day (every
12 hours) to related graft recipients. Adjusted ideal body weight [10] was
used to determine MMF dosing, and all doses were rounded to the nearest
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IMPDH activity. Participants were asked to take MMF at the same time daily.
MMF treatment started on day 0 and, in general, continued until day þ27
(related donor) or day þ40 (unrelated donor) at which time the MMF dose
was reduced by 10% per week in the absence of GVHD.
Most donor grafts were matched for HLA A, B, C, and DRB1 at high
resolution DNA typing and DQB1 by intermediate-resolution techniques,
with the following exceptions: 1 related and 2 unrelated donor grafts with
an antigen mismatch and 9 unrelated donor grafts with an allelic mismatch.
The median follow-up among participants at the time of last contact was
1.9 years (range, .6 to 3.8 years).
Sample Collection
Recipient pretransplant IMPDH activity is the IMPDH activity in
recipients’ PMNCs obtained on day4 before graft infusion and before MMF
administration. Three peripheral blood samples (5 mL in vacutainers
containing EDTA) were obtained to determine each recipient’s IMPDH ac-
tivity and also to characterize the within-individual variability in IMPDH
activity. No MMF was administered on this day. These IMPDH samples were
obtained concurrently with pharmacokinetic samples for 2-ﬂuoro-ara-A
(Supplemental Figure 1) after administration of the ﬁrst ﬂudarabine dose. In
4 participants, these samples were collected at 5minutes after the end of the
infusion, 90 minutes after the start of the infusion, and 6.5 hours after the
start of the infusion [11]. Sample collection occurred in the ambulatory
clinic, which necessitated a sampling schedule that would provide accept-
ably low withdrawal rates. The initial participant withdrawal rates were too
high, with participants stating that remaining at the clinic for the 6.5-hour
sample was a barrier to their continued participation. Thus, to lower
participant withdrawal rates, the sampling schedule was revised to collect
samples at the end of ﬂudarabine infusion, 5 minutes after the end of
infusion, and 90 minutes after the start of the infusion [11]. Most partici-
pants (77/86 [90%]) had 3 samples collected, demonstrating the success of
this revised sampling schedule. The number of samples collected in the
remaining participants was 4 samples in 1 participant, 2 samples in 8
participants, and 1 sample in 1 participant.
Chemicals and Reagents
Acetonitrile, ammonium acetate, methanol, sodium hydroxide, sodium
phosphate monobasic, ammonium hydroxide, and potassium chloride were
all purchased from Thermo Fisher (Waltham, MA). IMP, XMP, adenosine
monophosphate (AMP), 8-bromo-adenosine 50-monophosphate (BMP, inter-
nal standard), and NADwere obtained from Sigma (St. Louis, MO). Dulbecco’s
PBS was purchased from Invitrogen (Grand Island, NY). Ficoll Hypaque so-
lution (density 1.077 g/mL) was obtained from GE Healthcare (Uppsala,
Sweden). All chemicals were of reagent grade or better.
Isolation of Human PMNCs
Blood samples were stored at 4C until processing. PMNCswere isolated
within 6 hours of collection and were isolated by ﬁrst diluting blood in PBS
at a 1:1 v/v ratio and subsequently layering atop Ficoll. The height ratio of
Ficoll to diluted whole blood sample was 3:4. This suspension was then
centrifuged at 298 g for 30 minutes at 22C. PMNCs were collected from the
interface and diluted to a volume of 10 mL with PBS as a wash and centri-
fuged at 405 g for 15minutes at 22C. To facilitate cell counting and limit the
variability in cell concentration, all but 1.1 mL of the supernatant was
removed. The PMNC pellet was resuspended in the remaining 1.1 mL of PBS,
and 1.0mL of the PBS-cell slurry was transferred to a 2-mL tube. WBC counts
in this sample were quantitated using an ABX Micro 60 (requires <10 mL;
Horiba Diagnostics, Irving, CA). After cell quantitation, the sample was
centrifuged at 325 g for 10 minutes at room temperature. From the cell
pellet, 920 mL of the supernatant was removed; distilled water was added to
adjust the cell concentration to .5  106 cells/mL lysate. The cells were
subsequently stored at 80C until incubation. After thawing, insoluble
fragments of disrupted cells were removed by centrifugation at 16,000 g for
2 minutes. The supernatant was kept at 4C (or onwet ice) until it was used
for the IMPDH activity assay.
Quantiﬁcation of IMPDH1 and IMPDH2 Messenger RNA in PMNCs
Total RNA was extracted from cells from 15 participants using the
MagMax-96 Total RNA Isolation Kit obtained from Life Technologies
(Carlsbad, CA). The RNA yield was not determined from PMNCs because
of low cell numbers. To concentrate the amount of total RNA isolated, RNA
was precipitated using 5 M ammonium acetate followed by the addition of
5 mg/mL glycogen and 2 times the volume of ethanol. The tubes were then
placed in a 20C freezer for at least 25 minutes and then centrifuged at
15,000 g for 15 minutes. The supernatant was carefully removed, and the
pellet was air-dried and resuspended in elution buffer. The generation of
cDNA was performed using SuperScript III First-Strand Synthesis System(Life Technologies). Gene-speciﬁc TaqMan Gene Expression Assays (Life
Technologies) were used to quantitate relative expression of the two IMPDH
gene isoforms, IMPDH1 (Hs00992210_m1) and IMPDH2 (Hs00168418_m1),
relative to the internal endogenous control b-glucuronidase (4333767F) on a
StepOnePlus Real-Time PCR System (Life Technologies). Samples were
analyzed in triplicate using .8 mL cDNA in a 10-mL reaction containing a
TaqMan Gene Expression Assay primer/probe set and TaqMan Gene
Expression Master Mix (Life Technologies). The methods for data analysis
were performed as described previously [12].
PMNC Incubation
IMPDH activity in PMNCs was determined from the conversion of IMP to
XMP according to a procedure adapted from Glander et al. [13] and Daxecker
et al. [14]. For each incubation, a fresh reaction mixture was prepared from
stock solutions: .8 mL IMP (6.0 mmol/L, stored at 20C), .8 mL NAD
(4.5 mmol/L, made fresh each day), 1.6 mL NaH2PO4 (120 mmol/L stored at
4C), and 1.6 mL KCl (300 mmol/L, stored at 4C); the pH was adjusted to 7.4
using 1 M NaOH, and the total volume was brought to 5.2 mL with deionized
water. From this 5.2 mL of reaction mixture, 130 mL was used for each incu-
bate. The enzymatic reactionwas started via the addition of 130 mL of reaction
mixture to 50 mL prewarmed (5 minutes) PMNC lysate (standard concentra-
tion of .5  106 cells/mL). After 2.5 hours at 37C, the enzymatic reaction was
terminated by the addition of 1250 mL methanol. Internal standard (20 mL of
130 pmol/mL BMP in deionized water) was then added to each incubate, and
then the mixture was centrifuged at 16,000 g for 10 minutes at 37C. The
supernatant was then transferred to 12  75 disposable culture tubes and
evaporated to dryness under a stream of air at 37C. The residue was then
dissolved in 75 mL of deionized water and 5 mL was injected on the LC-MS.
A quality control (QC) lysate was prepared by pooling PMNCs from 5
healthy volunteers. This lysate was run in triplicate with every incubation,
with the QCs for the incubation procedure, which were no substrate (IMP),
no NAD, and no PMNC lysate.
LC-MS Quantitation of XMP in PMNCs
The HPLC separation was performed on an HPLC/MS series 1100 system
equipped with a thermostatically controlled autosampler (Agilent Tech-
nologies, Santa Clara, CA). Agilent ChemStation (version B.01.03) was used
for instrument control. Separation was achieved using a Thermo Scientiﬁc
Hypercarb column (2.0 mm  100 mm  5 mm, part no. 35005-102130;
Thermo Scientiﬁc, Bellefonte, PA). Themobile phase consisted of acetonitrile
and .1 M ammonium acetate adjusted to pH 8.5 with ammonium hydroxide.
A gradient system was used starting at 5% acetonitrile for .5 minutes,
increasing to 30% at 4 minutes, held at 30% until 5 minutes, and then
returning to 5% at 5.1 minutes. The total run time was 10 minutes.
The injector was maintained at 4C. The injection volume was 5 mL. The
column thermostat was set to 30.0C, and the solvent ﬂow was maintained
at .3 mL/min. Within an incubate, the typical retention times were 4.3 mi-
nutes for XMP, 5.6 minutes for AMP, 5.1 minutes for IMP, 7.0 minutes for
BMP, and 7.5 minutes for NAD (Figure 1). Of note, the NAD was present in
much higher concentrations than the analytes of interest and did not
interfere with IMP, XMP, or AMP (Figure 1). Figure 2 shows the chromato-
grams from our QC lysate, with the various QC incubations of no substrate
(no IMP, Figure 2A), no NAD (Figure 2B), no PMNC lysate (Figure 2C), and an
incubation with all components (Figure 2D).
An Agilent G1946D mass selective detector (MSD) (Agilent Technologies)
atmospheric pressure ionization-electrospray in positive ion mode was used.
The temperatureof thedryinggas (nitrogen)wasmaintainedat350Cataﬂow
of 11 L/min. The nebulizing pressure was 35 psi, the capillary voltage was
2400 V, and the fragmentor voltage was 100 V. The MSD was run in the se-
lective ionmonitoringmode.Monitored ions includedm/z365 for the (MþHþ)
ionofXMP,m/z348 for the (MþHþ) ionofAMP, andm/z426 for the (MþHþ) ion
of BMP, the internal standard. The MSD conditions for quantiﬁcation were as
described above; the fragmentor and capillary voltage were optimized under
analytical conditions with Chemstation FIA software (Agilent Technologies).
An 8-point calibration curve was prepared by spiking reaction mixture
and deionized water with both XMP and AMP. The dynamic range of the
calibration curve for XMP was 0 to 2318 pmol and for AMP, 0 to 4748 pmol.
The calibration curves were processed identically to the incubation samples.
The respective relationship between the peak heights of XMP and BMP and
between AMP and BMP and their respective concentrations were analyzed by
second-order polynomial regression. The correlation coefﬁcient (R2) was used
to evaluate the linearity of the calibration curves and in all experiments was
>.9950. The limits of quantitation (signal-to-noise ratio > 60 and coefﬁcient
of variation [CV] < 2%) were 58 pmol for XMP and 102.5 pmol for AMP.
Method Validation
Long-term stability of analytes was determined by analyzing in triplicate
QC lysates that were stored at 80C for 27 months. The percent difference
Figure 1. Chromatogram showing separation of analytes (.0066 mM AMP, .66 mM IMP, .0032 mM XMP, .0138 mM BMP, and .5 mM NAD) in a QC incubate (ie, after
incubation with a QC lysate).
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QC lysates were subjected to 4 cycles of freezing at 80C and thawing at
room temperature. We found a decrease of 33.6% for XMP and a decrease of
30.8% for AMP. Therefore, all samples analyzed were processed without any
freezeethaw cycles.
The intraday and interday precisionwere assessed based on the CV. The
intraday precision was calculated using 12 replicates of the QC lysate on 6
different days. The intraday precision was 3.86% for XMP and 3.18% for AMP.
The interday precision was calculated over 40 separate incubations of 3
replicates of the QC lysates per incubation. The interday precision for the
incubation was 6.20% for XMP and 5.85% for AMP. The IMPDH activity was
determined with the following equation:
IMPDH activity ¼ produced XMP 10
6
incubation timemeasured cell count
XMP is expressed in pmol/L, incubation time in hours, measured cell
count in cells, and IMPDH activity in pmol/106 cells/h. XMP formation was
also normalized by AMP formation using the following equation:
IMPDH activity ¼ produced XMP=incubation time
produced AMP
In this equation, XMP is expressed in pmol/L, incubation time in hours,
and AMP in pmol/L.
For those sampleswithmore than 1 replicate, the CV for each samplewas
evaluated by dividing a PMNC lysate into 2 or 3 aliquots and conducting
separate incubations and LC-MS quantitation. Thus, the within-sample CV (ie,
replicate variability within 1 sample) characterizes the variability of the in-
cubation procedure and LC-MS assay. For this within-sample CV, the median
of the CV was 1.94% (range, .07% to 19.2%) when normalized by cell count (ie,
pmol/106 cells/h) and 1.45% (range, .08% to 44%)when normalized by AMP (ie,
pmol XMP/h/pmol AMP). Within-sample CV for activity normalized by AMP
could not be determined for 2 samples because of unmeasurable AMP con-
centration. For sampleswithmore than 1 replicate, the lowest IMPDH activity
divided by the highest IMPDH activity (ie, minimum/maximum) ranged from
72% to 100%, with a median of 96%. The average ( standard deviation) of
IMPDH activity was 840  337 pmol/106 cells/h for XMP/cells and .34  .14
pmol XMP/h/pmol AMP. Because the precision was similar between these 2
normalization methods, we chose to normalize all reported data by cell count
because it is more intuitive for clinicians and facilitates communication of
pretransplant recipient IMPDH as a predictive biomarker.
Clinical Outcomes
Clinical outcomes of interest were toxicity to MMF (ie, neutropenia,
cytomegalovirus [CMV] reactivation), efﬁcacy of MMF (ie, day þ28 donor T
cell chimerism, acute and chronic GVHD), and overall HCT outcomes (ie,
relapse, nonrelapse mortality, and overall survival). Neutropenia post-HCT
was assessed only through day þ28, because multiple potential confound-
ing variables (eg, viral infection or reactivation, corticosteroid therapy)
could affect the neutrophil count after day þ28. Neutropenia was evaluated
by examination of complete blood counts with differential and assessmentof absolute neutrophil count (ANC). CMV reactivation was also evaluated,
because it represents a signiﬁcant consequence of immunosuppressed sta-
tus; CMV serological status was assessed in each participant and donor
before HCT. All participants underwent weekly testing to detect the CMV
pp65 antigen for the ﬁrst 3 months after HCT.
On days þ28, þ56, and þ84 after HCT, or as clinically indicated, all
participants’ peripheral blood samples were assessed for the percentage of
donor CD3þ T cells present. Flow cytometry was used to sort CD3þ cells, and
chimerism was measured using PCR of polymorphic microsatellite regions
[15]. If donor CD3þ cells were less than or equal to 5% at any of the assessed
time points after HCT, then the participant was noted to have graft rejection.
Acute and chronic GVHD were graded according to established criteria
[16-18]. It is recognized that gastrointestinal GVHD and gastrointestinal MMF
toxicity have some similarities; however, studies have identiﬁed differences
between these conditions that can be used in clinical diagnosis [19-26]. The
gastroenterologists and pathologists worked closely to stay current with the
literature and to properly diagnosis gastrointestinal GVHD (Supplemental
Table 1). Hematological diseases were classiﬁed as low, standard, or high
risk of relapse per the Kahl criteria to evaluate relapse rate in a consistent
manner [27]. We deﬁned disease relapse or disease progression as disease
recurrence after complete remission or progression of persistent disease.Statistical Analysis
The association of various covariates with recipient pretransplant
IMPDH activity was evaluated via ANOVA and regression-based approaches.
Participant covariates assessed included sex, age at the time of HCT, diag-
nosis (categorized as high, intermediate, or low risk), donor graft (catego-
rized as related or unrelated), HCT comorbidity index, and recipient
pretransplant IMPDH messenger RNA (mRNA).
Recipient pretransplant IMPDH activity was treated as a ﬁxed covariate.
Cumulative incidence curves for acute GVHD were estimated using previ-
ously described methods [28]. Cox regression analysis was used to model
the impact of recipient pretransplant IMPDH activity on time-to-event
endpoints. Death and relapse were treated as competing risks for analysis
of acute and chronic GVHD. Relapse was treated as a competing risk for the
analysis of nonrelapsemortality. Logistic regressionwas used to evaluate the
relationship between IMPDH activity and the post-transplant neutrophil
nadir. The effects of recipient pretransplant IMPDH activity on hazard ratios
(HRs) and odds ratios (ORs) were expressed as the effect per doubling of
IMPDH activity. All reported P values are 2-sided, and those estimated from
regression models are derived from the Wald test. No adjustments were
made for multiple comparisons. Statistical analysis was performed using
SAS version 9.3 (SAS Institute, Cary, NC). All statistical tests were 2-tailed
with a statistical signiﬁcance level of .05.RESULTS
Participant Characteristics
Recipient pretransplant IMPDH activity was available
from 86 of 105 participants. Of those 19 participants without
Figure 2. Chromatograms of XMP, AMP, and BMP for IMPDH activity measurement in PMNCs. (A-C) QC incubates included in each incubation procedure. (A) No
substrate (ie, no IMP), (B) no NAD, and (C) no PMNC. (D) Results of an actual incubation.
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development, and samples were not collected in the
remaining 4 because of scheduling difﬁculties or patient
withdrawal. The characteristics of the 86 participants with
available recipient pretransplant IMPDH activity data are
summarized in Table 1. The conditioning regimen and post-
grafting immunosuppression were determined by the par-
ticipant’s HCT treatment protocol.
Recipient Pretransplant IMPDH Activity
We ﬁrst documented acceptable variability of the
analytical method to quantitate XMP and the incubation
procedure to consistently provide accurate XMP formationFigure 3. Between-individual variability of recipient pretransplant IMPDH activity in P
donor graft.(see Method Validation). We also evaluated the within-
individual variability from samples drawn over a 1.5- to 6-
hour time period. The within-individual variability was
calculated by dividing the lowest IMPDH activity sample by
the highest sample. Most participants (90%) had 3 samples
collected, with 4 samples collected in 1 participant, 2 sam-
ples in 8 participants, and 1 sample in 1 participant (see
Sample Collection). For the within-individual variability,
these samples were within 46% to 98% of each other; the
activities were within 90% of each other in 41 participants
(48%) and 80% of each other in 71 participants (83%). For each
participant, the recipient pretransplant IMPDH activity was
calculated by averaging the XMP formation rate normalizedMNC obtained before administration of a related (white) or an unrelated (gray)
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obtained within 1 day. Among all 86 participants, consider-
able between-individual variability (12.2-fold) was observed
(Figure 3).
Covariate Analysis
The association of age, sex, disease (categorized as high,
intermediate, or low risk), donor graft (related or unrelated),
HCT comorbidity index, and recipient pretransplant mRNA
with IMPDH activity were assessed. To achieve normal dis-
tribution, the extreme outlier (IMPDH activity >2500 pmol/
106 cells/h) was excluded. Only age showed a statistically
signiﬁcant correlation (P < .04) with R2 ¼ .05. Although this
reached statistical signiﬁcance, it is clinically irrelevant
because of the low R2 value. IMPDH1/2 mRNA was only
determined in 15 participants because of resource con-
straints resulting from the IMPDH activity method develop-
ment. For the 15 samples assayed, there was no signiﬁcant
correlation between IMPDH1/2 mRNA level and activity.
Clinical Outcomes
Association of IMPDH activity with various clinical out-
comes is shown in Table 2, Figure 4, Supplemental Figure 2,
and Supplemental Figure 3. Table 2 also describes the num-
ber of participants with each clinical outcome of interest.
Graft rejection occurred in 2 participants: 1 received a
related donor graft and 1 had an unrelated donor. Both
received MMF with cyclosporine, and their recipient pre-
transplant IMPDH activities were 571 and 925 pmol/
106 cells/h, respectively.
Of the 86 participants, 78 (17 related, 61 unrelated) had
an ANC nadir below 500/mL between days 8 and þ28. Of
those 78, 19 experienced their ANC nadir between days 8
and þ7 and 59 between days þ8 and þ28. Of the 86 partic-
ipants, 23 were CMV positive with a CMV-positive donor, 23
were CMV positivewith a CMV-negative donor, 13 were CMV
negative with a CMV-positive donor, and 27 were CMV
negative with a CMV-negative donor. Among the 46 partic-
ipants who were CMV seropositive before HCT, 30 (65%)
experienced CMV reactivation. Speciﬁcally, 5 of 10 seropos-
itive participants with related donors (50%) and 25 of 36with
unrelated donors (69%) experienced CMV reactivation. In
CMV-negative recipients with a CMV-positive donor, CMV
antigenemia was detected in 2 of 4 related (50%) and 1 of 9
unrelated (11%) donor graft recipients.
The median for day þ28 donor T cell chimerism was 88%
(range, 35% to 100%). Sixty-seven participants had acuteTable 2
Effect of Recipient Pretransplant IMPDH Activity on Clinical Outcomes
Clinical Outcome Number
of Events
OR/HR* (95% CI) P
Day þ28 T cell chimerism 95% 33 .17 (.1-.6) .003
Grades II to IV acute GVHD 60 .50 (.3-.9) .03
Grades III to IV acute GVHD 11 .30 (.1-.9) .03
Chronic GVHD 47 1.03 (.6-1.8) .91
Relapse 20 1.53 (.6-3.7) .35
ANC nadir < 165/mm3 44 .26 (.1-.7) .01
CMV reactivation 33 .48 (.3-.9) .02
Nonrelapse mortality 17 .58 (.2-1.5) .27
Overall mortality 30 1.04 (.5-2.2) .92
* Day þ28 T cell chimerism and neutropenia analyzed as binary endpoint
(OR), and all others as time-to-event endpoint (HR). OR and HR are effects
per doubling of recipient pretransplant IMPDH activity. All analyses
adjusted for Kahl risk category (low, standard, high), donorerecipient
gender (female to male, other), and donor (related, unrelated).GVHD with the median onset on day þ37. Of these, 60 par-
ticipants (16 related, 44 unrelated) had grades II to IV acute
GVHD and 11 (4 related, 7 unrelated) had grades III to IV
acute GVHD. Supplemental Table 1 includes detailed acute
GVHD information, speciﬁcally the organ affected and its
grade. Forty-seven participants had chronic GVHD. Twenty
participants relapsed; 6 had related donors and 14 had un-
related donors. Thirteen of these participants died of relapse,
4 of whom had a related donor and 9 of whom had an un-
related donor. Seventeen participants died of nonrelapse
mortality. Of these, 3 had a related donor and 14 had an
unrelated donor. At last follow-up, 56 participants were still
alive.
We sought to evaluate whether clinical outcomes were
associated with recipient pretransplant IMPDH activity.
Increasing IMPDH activity was associated with a decreased
likelihood of day þ28 T cell donor chimerism 95%, with an
OR of .17 per doubling of IMPDH activity (95% conﬁdence
interval [CI], .1 to .6; P¼ .003). Thus, the odds of experiencing
day þ28 T cell chimerism 95% were decreased by 83% with
each doubling of IMPDH activity. Increasing IMPDH activity
was associated with a lower rate of grades II to IV acute
GVHD (HR ¼ .50 per doubling of IMPDH activity; 95% CI, .3 to
.9; P ¼ .03) and grades III to IV acute GHVD (HR ¼ .30 per
doubling of IMPDH activity; 95% CI, .1 to .9; P ¼ .03).
Increasing IMPDH activity was associated with a decreased
risk of neutrophil nadir <165/mm3 (P ¼ .01), with an OR of
.26 (95% CI, .1 to .7) per doubling of IMPDH activity. Thus, the
odds of experiencing a neutrophil nadir <165/mm3 were
decreased 74% with each doubling of IMPDH activity. Simi-
larly, higher IMPDH activity was associated with a lower rate
of CMV reactivation (HR ¼ .48 per doubling of IMPDH ac-
tivity; 95% CI, .3 to .9; P ¼ .02). IMPDH activity was not,
however, statistically associated with chronic GVHD, relapse,
nonrelapse mortality, or overall mortality (Table 2).
DISCUSSION
In this analysis we evaluated recipient pretransplant
IMPDH activity in 86 consecutive participants who were
given nonmyeloablative conditioning before receiving allo-
geneic grafts to treat hematological malignancies. To our
knowledge, this is the ﬁrst analysis of recipient pretransplant
IMPDH in HCT participants. There was considerable
between-individual variability in the IMPDH activity
(Figure 3). Low recipient pretransplant IMPDH activity was
associated with increased day þ28 T cell chimerism, more
acute GVHD, lower neutrophil nadirs, and more CMV reac-
tivation but not with chronic GVHD, relapse, nonrelapse
mortality, or overall mortality (Table 2 and Figure 4).
The role of MMF as postgrafting immunosuppression in
HCT recipients has gradually increased over the past 15 years
[29]. There is considerable interindividual variability in MPA
plasma exposure with weight-based dosing of either intra-
venous or oral MMF in HCT recipients [10,30]. Pharmaco-
dynamic data suggest a relationship between clinical
outcomes and MPA plasma exposure (as reviewed in
McDermott et al. [31]), and some HCT centers personalize
MMF doses to a target MPA exposure [32]. We recently
observed that low total MPA plasma exposurewas associated
with increased grades III to IV acute GVHD and increased
nonrelapse mortality in nonmyeloabative HCT recipients
with an unrelated donor graft. In patients receiving a related
donor graft after nonmyeloablative conditioning, however,
total MPA plasma exposure was not associated with clinical
outcomes, and additional biomarkers, such as recipient
Figure 4. Clinical outcomes and recipient pretransplant IMPDH before administration of a related (white) or unrelated (gray) donor graft: (A) day þ28 donor T cell
chimerism, (B) acute GVHD grade, (C) neutrophil nadir, and (D) CMV reactivation.
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nately, because of a concurrent clinical trial comparing TBI
versus ﬂudarabine/TBI in related donor graft recipients [33],
there is a paucity of nonmyeloablative HCT participants
receiving an related donor graft in this reported population
(Table 1).
PMNCs are the predominant cell population used to
measure IMPDH activity [8,13,14,34], although Vethe and
Bergan [35] evaluated IMPDH activity in CD4þ cells. To our
knowledge, IMPDH activity has only been assessed in these
2 cell populations, but mRNA expression of both IMPDH1 and
IMPDH2 has been more extensively studied. MPA inhibits
both IMPDH1 and IMPDH2, which are ubiquitously
expressed and have similar catalytic activity in vitro but do
differ in their tissue expression [36-40]. Compared with
hepatic mRNA expression, IMPDH1 expression is higher in
the pancreas, colon, and peripheral blood leukocytes, and
IMPDH2 expression is higher in the pancreas, kidney, and
skeletal muscle [36]. Both IMPDH1 and IMPDH2
are expressed in the small intestine and colon. Notably,
grades II to IV gastrointestinal GVHD was infrequent
(Supplemental Table 1).
Developing a rapid and robust analytical method that can
be used in clinical practice is a necessity before evaluating
IMPDH activity as a biomarker. The assays for IMPDH activity
can be divided into either radiometric or nonradiometric
quantitation methods [13,34]. The radiometric methods
require low sample volume and also maintain intracellular
MPA concentration. Substantive difﬁculties with storage of
control and/or participant samples for longer than 8 hours,however, make these methods suboptimal. Nonradioactive
liquid chromatography procedures such as ours are based on
the quantitation of produced XMP in cell extracts supple-
mented with the substrate IMP and cosubstrate NADþ in
excess and subsequently incubated. Laverdière et al. [8]
described a LC-coupled tandem MS method for the quanti-
ﬁcation of XMP and AMP (for normalization) in PMNC ly-
sates, including those from 19 HCT recipients. Our XMP assay
had similar reproducibility to that of Laverdière (CV < 7.5%)
[8]. Our chromatographic conditions using the Hypercarb
column provided excellent baseline separation of XMP from
IMP and other endogenous adenosine-phosphate species
(Figures 1 and 2). The carbon solid phase of the Hypercarb
column eliminates the need for the ion pairing reagents,
which can often be difﬁcult to remove from the HPLC system.
We chose not to use AMP to normalize results because pre-
cision was similar between normalization by cell count or by
AMP concentration. We chose to normalize all reported data
by cell count because it is more intuitive for clinicians and
facilitates communication of pretransplant recipient IMPDH
as a predictive biomarker.
Recipient pretransplant IMPDH activity has several ad-
vantages as a biomarker. First, an adequate number of PMNCs
can be obtained because samples are drawn before admin-
istration of nonmyeloablative (ie, ﬂudarabine/TBI) condi-
tioning. The second advantage for recipient pretransplant
IMPDH as a biomarker is that it would not have the same
rapid turnaround time requirements for MPA plasma con-
centrations for MMF dose personalization to a target MPA
exposure. High recipient IMPDH activity is associated with
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only 2 rejections occurred, and thus this relationship could
not be evaluated.
Low recipient pretransplant IMPDH activity was associ-
ated with increased day þ28 T cell chimerism, more acute
GVHD, lower neutrophil nadirs, and more CMV reactivation
but not with chronic GVHD, relapse, nonrelapse mortality, or
overall mortality (Table 2 and Figure 4). An alternative way to
present these ﬁndings is that higher recipient pretransplant
IMPDH activity was associated with lower day þ28 T cell
chimerism, less acute GVHD, higher neutrophil nadirs, and
lower CMV reactivation. If a recipient is not sensitive to
MPAdpotentially as demonstrated by a high pretransplant
IMPDH activitydfewer immunologically competent cells
will die [41], and therefore more of the recipient’s immu-
nologically competent cells are present to allow for tolerance
between the recipient and donor cells. Thus, the trends be-
tween IMPDH activity and day þ28 donor T cell chimerism,
neutrophil nadir, or CMV reactivation are not unexpected.
At ﬁrst, the ﬁnding that higher recipient pretransplant
IMPDH activity is associatedwith less acute GVHD seems less
intuitive. There are at least 2 mechanistic hypotheses to
explain this ﬁnding. Previously, we have shown that high
donor T cell chimerism on day þ28 was associated with an
increased probability of acute GVHD in 120 non-
myeloablative HCT recipients [5,7]. Based on these previous
results and the association of increasing pretransplant
IMPDH activity with lower day þ28 donor T cell chimerism
(Table 2), the association of a lower risk of acute GVHD with
increasing pretransplant IMPDH activity is not surprising.
Furthermore, these results agree with recent data regarding
the inﬂuence of peritransplant neutrophil and lymphocyte
counts upon the risk of acute GVHD or relapse in 459 non-
myeloablative HCT recipients [7]. Storb et al. found that low
neutrophil nadirs within the ﬁrst 3 weeks post-HCT had
signiﬁcant associations with increased risk of acute GVHD
and 5-year nonrelapse mortality but not with relapse. In the
study presented here, recipients with higher pretransplant
IMPDH activity have higher neutrophil nadirs and therefore a
lower risk of acute GVHD. Thus, the association between
IMPDH activity and acute GVHD has at least 2 mechanistic
rationales.
In addition, we hypothesize that recipients with higher
pretransplant IMPDH activity have fewer immunologically
competent cells die, allowing more of the recipient’s
immunologically competent cells to be present to build
tolerance between the recipient and donor cells. Evaluating
IMPDH activity early after the graft infusion may provide
some insight regarding this hypothesis. We sought to eval-
uate IMPDH activity on day þ2, but participants had too few
cells to isolate PMNC successfully. Future studies could seek
to evaluate IMPDH activity and Tcell chimerism immediately
after adequate cell numbers are present, possibly within
24 hours of engraftment. In addition, future work should
address the effect of MPA-based postgrafting immunosup-
pression on various T cell subsets. Within human and animal
models, there is accumulating evidence that regulatory T
cells are involved in the development of GVHD [42,43].
In vitro data in human PMNCs indicate that MPA might
favorably inﬂuence the balance between regulatory T cells
and the newly identiﬁed subset of IL-17esecreting helper T
cells [44]. Separate in vitro studies suggest that MPA hinders
the antigen presenting and lymph node homing capacities of
human blood myeloid dendritic cells, which may promote
allograft tolerance by interfering with the initiation ofacquired immunity [45]. The translation of these in vitro
ﬁndings to nonmyeloablative HCT recipients receiving MPA-
based postgrafting immunosuppression could offer novel
insight to the pathophysiology of GVHD. Because of the
complexity and multiscale nature of the human immune
response, the translation of these in vitro ﬁndings could
beneﬁt from the use of mathematical modeling and simu-
lation to gain a mechanistic understanding.
Such amechanistic understanding can be gained from the
recently developed fully integrated immune response model,
created with a systems biology approach usingmathematical
models developed by integrating models of the humoral side
of the immune response, the cellular side of immune
response, and for cytokine kinetics [46]. This model accu-
rately simulated the immune response to a tuberculosis
infection, a bloodborne pathogen, immune-mediated tumor
elimination, and tumor removal with regulatory T cells.
Future work should include the application of immune
models to allogeneic HCT. As a ﬁrst step, we characterized
recipient pretransplant IMPDH along with additional bio-
markers to begin collecting adequate data to build such im-
mune models. A limitation of our work was not evaluating
donor IMPDH activity, whichwould be important after donor
engraftment occurs. Because most of our donors were un-
related, however, PMNCs from the donor were not available
pretransplant.
In conclusion, we developed a method with adequate
sensitivity to quantitate recipient pretransplant IMPDH ac-
tivity. We found that recipient pretransplant IMPDH activity
was associated with an increased risk of neutropenia, CMV
reactivation, and acute GVHD in nonmyeloablative HCT re-
cipients. Because of the variable outcomes, future prospec-
tive trials should address the clinical beneﬁt of alternative
postgrafting immunosuppression or higher initial oral MMF
doses to patients with high recipient pretransplant IMPDH
activity to improve clinical outcomes in nonmyeloablative
HCT recipients.
ACKNOWLEDGMENTS
The authors thank Thomas Kalhorn and Candace N. Cor-
nell Kristensson for their contributions to the initial devel-
opment of the LC-MS method and Gary Schoch for his data
management expertise. The contribution of George B.
McDonald for his assistance with responding to reviewer
comments is also acknowledged. The authors also thank the
participants and caregivers for their participation as well as
the nurses and support staff for their excellent care of the
patients.
Financial disclosure: Supported by grants from the Na-
tional Institutes of Health (HL91744, HL91744S1, CA18029,
CA78902, HL36444, HL093294, CA015704).
SUPPLEMENTARY DATA
Supplementary data related to this article can be found
online at http://dx.doi.org/10.1016/j.bbmt.2014.05.032.
REFERENCES
1. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unre-
lated donor hematopoietic cell transplantation after nonmyeloablative
conditioning for patients with hematologic malignancies. Blood. 2003;
102:2021-2030.
2. Nash RA, Johnston L, Parker P, et al. A phase I/II study of mycophenolate
mofetil in combination with cyclosporine for prophylaxis of acute
graft-versus-host disease after myeloablative conditioning and alloge-
neic hematopoietic cell transplantation. Biol Blood Marrow Transplant.
2005;11:495-505.
M.J. Bemer et al. / Biol Blood Marrow Transplant 20 (2014) 1544e155215523. Mineishi S. Overcoming the age barrier in hematopoietic stem cell
transplantation: progress, but still a long way to go. JAMA. 2011;306:
1918-1920.
4. Baron F, Sandmaier BM. Chimerism and outcomes after allogeneic
hematopoietic cell transplantation following nonmyeloablative condi-
tioning. Leukemia. 2006;20:1690-1700.
5. Baron F, Baker JE, Storb R, et al. Kinetics of engraftment in patients with
hematologic malignancies given allogeneic hematopoietic cell trans-
plantation after nonmyeloablative conditioning. Blood. 2004;104:
2254-2262.
6. Maris MB, Sandmaier BM, Storer BE, et al. Unrelated donor granulocyte
colony-stimulating factor-mobilized peripheral blood mononuclear cell
transplantation after nonmyeloablative conditioning: the effect of
postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Trans-
plant. 2006;12:454-465.
7. Storb R, Gyurkocza B, Storer BE, et al. Allogeneic hematopoietic cell
transplantation following minimal intensity conditioning: predicting
acute graft-versus-host disease and graft-versus-tumor effects. Biol
Blood Marrow Transplant. 2013;19:792-798.
8. Laverdière I, Caron P, Couture F, et al. Liquid chromatography-coupled
tandem mass spectrometry based assay to evaluate inosine-5’-mono-
phosphate dehydrogenase activity in peripheral blood mononuclear
cells from stem cell transplant recipients. Anal Chem. 2012;84:216-223.
9. Glander P, Hambach P, Braun KP, et al. Pre-transplant inosine mono-
phosphate dehydrogenase activity is associated with clinical outcome
after renal transplantation. Am J Transplant. 2004;4:2045-2051.
10. Li H, Mager DE, Sandmaier BM, et al. Population pharmacokinetics and
dose optimization of mycophenolic acid in HCT recipients receiving
oral mycophenolate mofetil. J Clin Pharmacol. 2013;53:393-402.
11. Salinger DH, Blough DK, Vicini P, et al. A limited sampling schedule to
estimate individual pharmacokinetic parameters of ﬂudarabine in he-
matopoietic cell transplant patients. Clin Cancer Res. 2009;15:
5280-5287.
12. Woodahl EL, Wang J, Heimfeld S, et al. A novel phenotypic method to
determine ﬂudarabine triphosphate accumulation in T-lymphocytes
from hematopoietic cell transplantation patients. Cancer Chemother
Pharmacol. 2009;63:391-401.
13. Glander P, Sombogaard F, Budde K, et al. Improved assay for the
nonradioactive determination of inosine 5’-monophosphate dehydro-
genase activity in peripheral blood mononuclear cells. Ther Drug Monit.
2009;31:351-359.
14. Daxecker H, Raab M, Muller MM. Inﬂuence of mycophenolic acid on
inosine 5’-monophosphate dehydrogenase activity in human periph-
eral blood mononuclear cells. Clin Chim Acta. 2002;318:71-77.
15. Bryant E, Martin PJ. Documentation of engraftment and characteriza-
tion of chimerism following hematopoietic cell transplantation. In:
Thomas ED, Blume KG, Forman SJ, editors. Hematopoietic cell trans-
plantation. Malden, MA: Blackwell Science; 1999. p. 197-206.
16. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference
on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
17. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host dis-
ease and other late complications of bone marrow transplantation.
Semin Hematol. 1991;28:250-259.
18. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-
versus-host disease in human recipients of marrow from HL-A-
matched sibling donors. Transplantation. 1974;18:295-304.
19. Parﬁtt JR, Jayakumar S, Driman DK. Mycophenolate mofetil-related
gastrointestinal mucosal injury: variable injury patterns, including
graft-versus-host disease-like changes. Am J Surg Pathol. 2008;32:
1367-1372.
20. Nguyen T, Park JY, Scudiere JR, Montgomery E. Mycophenolic acid
(cellcept and myofortic) induced injury of the upper GI tract. Am J Surg
Pathol. 2009;33:1355-1363.
21. Al-Absi AI, Cooke CR, Wall BM, et al. Patterns of injury in mycophe-
nolate mofetil-related colitis. Transplant Proc. 2010;42:3591-3593.
22. Selbst MK, Ahrens WA, Robert ME, et al. Spectrum of histologic changes
in colonic biopsies in patients treated with mycophenolate mofetil.
Mod Pathol. 2009;22:737-743.
23. Patra S, Vij M, Sukanya B, Kapoor D. Mycophenolate mofetil-induced
colitis with graft versus host disease-like features in a liver trans-
plant recipient. Indian J Pathol Microbiol. 2012;55:506-508.24. Cox GJ, Matsui SM, Lo RS, et al. Etiology and outcome of diarrhea after
marrow transplantation: a prospective study. Gastroenterology. 1994;
107:1398-1407.
25. Ponec RJ, Hackman RC, McDonald GB. Endoscopic and histologic
diagnosis of intestinal graft-versus-host disease after marrow trans-
plantation. Gastrointest Endosc. 1999;49:612-621.
26. Star KV, Ho VT, Wang HH, Odze RD. Histologic features in colon bi-
opsies can discriminate mycophenolate from GVHD-induced colitis.
Am J Surg Pathol. 2013;37:1319-1328.
27. Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk in patients with
malignant diseases given allogeneic hematopoietic cell transplantation
after nonmyeloablative conditioning. Blood. 2007;110:2744-2748.
28. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure
probabilities in the presence of competing risks: new representations
of old estimators. Stat Med. 1999;18:695-706.
29. Deeg HJ, Maris MB, Scott BL, Warren EH. Optimization of allogeneic
transplant conditioning: not the time for dogma. Leukemia. 2006;20:
1701-1705.
30. Li H, Mager DE, Bemer MJ, et al. A limited sampling schedule to esti-
mate mycophenolic acid area under the concentration-time curve in
hematopoietic cell transplantation recipients. J Clin Pharmacol. 2011;
52:1654-1664.
31. McDermott CL, Sandmaier BM, Storer B, et al. Nonrelapse mortality and
mycophenolic acid exposure in nonmyeloablative hematopoietic cell
transplantation. Biol Blood Marrow Transplant. 2013;19:1159-1166.
32. Haentzschel I, Freiberg-Richter J, Platzbecker U, et al. Targeting
mycophenolate mofetil for graft-versus-host disease prophylaxis after
allogeneic blood stem cell transplantation. Bone Marrow Transplant.
2008;42:113-120.
33. Kornblit B, Maloney DG, Storb R, et al. Fludarabine and 2-Gy TBI is
superior to 2 Gy TBI as conditioning for HLA-matched related he-
matopoietic cell transplantation: a phase III randomized trial. Biol Blood
Marrow Transplant. 2013;19:1340-1347.
34. Glander P, Braun KP, Hambach P, et al. Non-radioactive determination
of inosine 5’-monophosphate dehydro-genase (IMPDH) in peripheral
mononuclear cells. Clin Biochem. 2001;34:543-549.
35. Vethe NT, Bergan S. Determination of inosine monophosphate dehy-
drogenase activity in human CD4þ cells isolated from whole blood
during mycophenolic acid therapy. Ther Drug Monit. 2006;28:608-613.
36. Senda M, Natsumeda Y. Tissue-differential expression of two distinct
genes for human IMP dehydrogenase (E.C.1.1.1.205). Life Sci. 1994;54:
1917-1926.
37. Collart FR, Huberman E. Cloning and sequence analysis of the human
and Chinese hamster inosine-5’-monophosphate dehydrogenase
cDNAs. J Biol Chem. 1988;263:15769-15772.
38. Natsumeda Y, Ohno S, Kawasaki H, et al. Two distinct cDNAs for human
IMP dehydrogenase. J Biol Chem. 1990;265:5292-5295.
39. Hager PW, Collart FR, Huberman E, Mitchell BS. Recombinant human
inosine monophosphate dehydrogenase type I and type II proteins.
Puriﬁcation and characterization of inhibitor binding. Biochem Phar-
macol. 1995;49:1323-1329.
40. Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I
and type II IMP dehydrogenases. J Biol Chem. 1993;268:27286-27290.
41. Baron F, Little MT, Storb R. Kinetics of engraftment following allogeneic
hematopoietic cell transplantation with reduced-intensity or non-
myeloablative conditioning. Blood Rev. 2005;19:153-164.
42. Le NT, Chao N. Regulating regulatory T cells. Bone Marrow Transplant.
2007;39:1-9.
43. Tsang JY, Tanriver Y, Jiang S, et al. Conferring indirect allospeciﬁcity on
CD4þCD25þ Tregs by TCR gene transfer favors transplantation toler-
ance in mice. J Clin Invest. 2008;118:3619-3628.
44. Abadja F, Videcoq C, Alamartine E, et al. Differential effect of cyclo-
sporine and mycophenolic acid on the human regulatory T cells and
TH-17 cells balance. Transplant Proc. 2009;41:3367-3370.
45. Cicinnati VR, Hou J, Lindemann M, et al. Mycophenolic acid impedes
the antigen presenting and lymph node homing capacities of human
blood myeloid dendritic cells. Transplantation. 2009;88:504-513.
46. Palsson S, Hickling TP, Bradshaw-Pierce EL, et al. The development of a
fully-integrated immune response model (FIRM) simulator of the im-
mune response through integration of multiple subset models. BMC
Syst Biol. 2013;7:95.
